HLI and LEV Centenarian Study: What Is Confirmed and What the Protocol Still Needs
HLI and LEV announced multi-omic research using centenarian blood samples. The release confirms the partnership and methods, but omits sample size, endpoints, timeline, and a public protocol.
Review note, August 28, 2026: WLC rewrote this announcement as a protocol appraisal. Biological mechanisms, database superlatives, market predictions, and clinical translation claims not established by the release were removed.
Human Longevity, Inc. and the LEV Foundation announced a research collaboration on March 25, 2026. They plan to analyze blood from centenarians aged 100 or older and supercentenarians aged 110 or older using genomics, proteomics, and other multi-omic methods.
The announcement is a plan from the participating organizations, not a study result.
What the announcement confirms
The release establishes that:
- HLI and LEV intend to collaborate on exceptional-longevity research;
- blood samples from centenarians and supercentenarians will be studied;
- the analysis will combine genomic, proteomic, and other multi-omic data;
- broader population cohorts are intended as comparators;
- Natalie Coles-de Grey will lead the work;
- Natalie Coles-de Grey and Aubrey de Grey will join HLI’s scientific advisory board;
- and the organizations expect the work to lay a foundation for later longitudinal research.
That is enough to describe the collaboration. It is not enough to evaluate the validity, reproducibility, or clinical usefulness of its future findings.
What a public protocol still needs
The press release does not report several details needed to appraise the research.
| Missing field | Why it matters |
|---|---|
| Sample size and recruitment source | Determines statistical power, selection bias, and whether the cohort represents more than a narrow survivor group |
| Comparator definition | Age, sex, ancestry, geography, health status, medication, and lifestyle can influence multi-omic differences |
| Primary endpoints | Thousands of molecular measurements create many opportunities for chance associations |
| Prespecified analysis | A statistical plan, validation cohort, and multiple-testing correction help distinguish discovery from overfitting |
| Timeline and follow-up | A cross-sectional comparison cannot show whether a marker predicted later health or survival |
| Data and code access | Independent replication depends on documented methods and accessible results |
| Funding and governance | Commercial and organizational roles should be disclosed alongside publication and data-use terms |
| Registration or protocol location | A public record would allow readers to compare planned methods with reported outcomes |
These omissions are not proof that the underlying study is poor. They are reasons to wait for a protocol, registration, preprint, or peer-reviewed paper before drawing conclusions.
Why centenarian comparisons are scientifically difficult
People who reach 100 are a selected survivor population. Their biology reflects genetics, environment, healthcare, behaviour, historical exposure, and chance across a century.
A molecular feature that differs between centenarians and younger or shorter-lived comparators may be:
- a contributor to survival;
- a consequence of surviving;
- associated with medication, diet, infection history, or another confounder;
- or a statistical finding that does not replicate.
Multi-omic analysis can generate hypotheses and combinations of markers. It cannot, by itself, show that changing one marker will make a younger person live longer.
A useful transparency benchmark
The New England Centenarian Study shows what a mature cohort program can make visible. Its official site describes work established in 1995, NIH-funded studies, recruitment information, publications, data-sharing resources, and an explicit effort to improve participant diversity.
The HLI and LEV project does not need to copy that design. It should eventually provide comparable clarity about cohort construction, governance, analysis, and access.
What this means for patients today
The announcement does not validate a longevity test, biomarker target, supplement, or treatment. No outcome data are reported, and the proposed work is described as a foundation for future longitudinal studies.
If a clinic cites this collaboration to support a commercial recommendation, ask:
- Which published result supports the exact test or intervention?
- Was the finding replicated outside the discovery cohort?
- Does the marker predict a patient-relevant outcome prospectively?
- Is there evidence that changing it improves health?
- Is the commercial test analytically and clinically validated?
HLI also sells consumer health programs. That does not invalidate its research, but it makes a clear separation between exploratory findings and product claims especially important. For current program claims and follow-up questions, see the WLC Human Longevity assessment guide.
Current verdict
This is a confirmed research collaboration with a promising question and an unpublished protocol. The next meaningful evidence will be a detailed study record and results that can be independently assessed, not another announcement about the platform.
Main source: Human Longevity and LEV Foundation press release, published March 25, 2026 and reviewed August 28, 2026. Cohort-transparency comparator: New England Centenarian Study.